Citations

Clear

3942 citation(s) found for "To, Van".

Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
Mantovani, LG , Cozzolino, Paolo , Ferrara, Pietro , Virdone, Saverio , Camm, A. John , Verheugt, Freek W.A. , Bassand, Jean‐Pierre , Turpie, Alexander G.G., Hacke, Werner, Kayani, Gloria , Goldhaber, Samuel Z. , Goto, Shinya , Pieper, Karen S. , Haas, Sylvia , Eickels, Martin van, Kakkar, Ajay K. , Investigators, on behalf of the GARFIELD-AF, Verheugt, Freek W A , Gersh, Bernard J. , Fox, Keith A.A. , Investigators, on behalf of the GARFIELD-AF

Mayo Clinic

Healthcare | February 22, 2023 | Volume: 11 | Issue: 5 | Pages: 638

10.3390/healthcare11050638 | PMID 36900643 Get It

The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF registry. A prospective cohort study was conducted to characterize HCRU in AF patients enrolled in sequential cohorts from 2012 to 2016 in 35 countries. Components of HCRU studied were hospital admissions, outpatient care visits, and diagnostic and interventional procedures occurring during follow-up. AF-related HCRU was reported as the percentage of patients demonstrating at least one event and was quantified as rate-per-patient-per-year (PPPY) over time. A total of 49,574 patients was analyzed, having an overall median follow-up of 719 days. Almost all patients (99.5%) had at least one outpatient care visit, while hospital admissions were the second most frequent medical contact, with similar proportions in North America (37.5%) and Europe (37.2%), and slightly higher in the other GARFIELD-AF countries (42.0%; namely Australia, Egypt, and South Africa). Asia and Latin America showed lower percentages of hospitalizations, outpatient care visits, and diagnostic and interventional procedures. Analyses of GARFIELD-AF highlighted the vast AF-related HCRU, underlying significant geographical differences in the type, quantity, and frequency of AF-related HCRU. These differences were likely attributable to health service availability and differing models of care.
Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry
Breysem, Luc , Keyzer, Frederik De , Schellekens, Pieter , Dachy, Angélique , Vennekens, Rudi , Irazabal, María V. , Ongeval, Chantal Van , Harris, Peter C. , De Keyzer, Frederik , Irazabal, Maria V , Mekahli, Djalila , Harris, Peter C , Rechter, Stéphanie De , Janssens, Peter , Bammens, Bert

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 17, 2023 | Volume: 18 | Issue: 5 | Pages: 581-591

10.2215/cjn.0000000000000122 | PMID 36800517 Get It

Background Height-adjusted total kidney volume (htTKV) measured by imaging defined as Mayo Imaging Class (MIC) is a validated prognostic measure for autosomal dominant polycystic kidney disease (ADPKD) in adults to predict and stratify disease progression. However, no stratification tool is currently available in pediatric ADPKD. Because magnetic resonance imaging and computed tomography in children are difficult, we propose a novel 3D ultrasound-based pediatric Leuven Imaging Classification to complement the MIC. Methods A prospective study cohort of 74 patients with genotyped ADPKD (37 female) was followed longitudinally with ultrasound, including 3D ultrasound, and they underwent in total 247 3D ultrasound assessments, with patients' median age (interquartile range [IQR]) at diagnosis of 3 (IQR, 0–9) years and at first 3D ultrasound evaluation of 10 (IQR, 5–14) years. First, data matching was done to the published MIC classification, followed by subsequent optimization of parameters and model type. Results PKD1 was confirmed in 70 patients (95%), PKD2 in three (4%), and glucosidase IIα unit only once (1%). Over these 247 evaluations, the median height was 143 (IQR, 122–166) cm and total kidney volume was 236 (IQR, 144–344) ml, leading to an htTKV of 161 (IQR, 117–208) ml/m. Applying the adult Mayo classification in children younger than 15 years strongly underestimated ADPKD severity, even with correction for height. We therefore optimized the model with our pediatric data and eventually validated it with data of young patients from Mayo Clinic and the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease used to establish the MIC. Conclusions We proposed a five-level Leuven Imaging Classification ADPKD pediatric model as a novel classification tool on the basis of patients' age and 3D ultrasound-htTKV for reliable discrimination of childhood ADPKD severity.
21. Efficacy of Commonly Utilized Resources in Preparation for the Plastic Surgery In-Service Examination
Spronsen, Nicole Van , Shrout, Maxwell, Rangel, India , Gill, Vikram, Harrington, M., Smith, Anthony A., Kandi, Lyndsay A. , Adeleye, Olufunmilola

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | February 16, 2023 | Volume: 11 | Issue: 2S | Pages: 13-14

10.1097/01.gox.0000921632.71209.6a Get It

Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy
Bothun, Erick D. , Repka, Michael X. , Kraker, Raymond T. , Leske, David A. , Li, Zhuokai , Astle, William F., Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Galvin, Jennifer, Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Mohney, Brian G., Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Sutherland, Desirae R. , Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Salchow, Daniel J. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Yen, Kimberly G., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Haider, Kathryn M. , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Wu, Rui, Hatt, Sarah R. , Freedman, Sharon F. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Saunders, Richard Anthony , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | February 16, 2023 | Volume: 141 | Issue: 4 | Pages: 324

10.1001/jamaophthalmol.2022.6413 | PMID 36795393 Get It

ImportanceGlaucoma can develop following cataract removal in children.ObjectiveTo assess the cumulative incidence of glaucoma-related adverse events (defined as glaucoma or glaucoma suspect) and factors associated with risk of these adverse events in the first 5 years after lensectomy prior to 13 years of age.Design, Setting, and ParticipantsThis cohort study used longitudinal registry data collected at enrollment and annually for 5 years from 45 institutional and 16 community sites. Participants were children aged 12 years or younger with at least 1 office visit after lensectomy from June 2012 to July 2015. Data were analyzed from February through December 2022.ExposuresUsual clinical care after lensectomy.Main Outcomes and MeasuresThe main outcomes were cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of these adverse events.ResultsThe study included 810 children (1049 eyes); 443 eyes of 321 children (55% female; mean [SD] age, 0.89 [1.97] years) were aphakic after lensectomy, and 606 eyes of 489 children (53% male; mean [SD] age, 5.65 [3.32] years) were pseudophakic. The 5-year cumulative incidence of glaucoma-related adverse events was 29% (95% CI, 25%-34%) in 443 eyes with aphakia and 7% (95% CI, 5%-9%) in 606 eyes with pseudophakia; 7% (95% CI, 5%-10%) of aphakic eyes and 3% (95% CI, 2%-5%) of pseudophakic eyes were diagnosed as glaucoma suspect. Among aphakic eyes, a higher risk for glaucoma-related adverse events was associated with 4 of 8 factors, including age less than 3 months (vs ≥3 months: adjusted hazard ratio [aHR], 2.88; 99% CI, 1.57-5.23), abnormal anterior segment (vs normal: aHR, 2.88; 99% CI, 1.56-5.30), intraoperative complications at time of lensectomy (vs none; aHR, 2.25; 99% CI, 1.04-4.87), and bilaterality (vs unilaterality: aHR, 1.88; 99% CI, 1.02-3.48). Neither of the 2 factors evaluated for pseudophakic eyes, laterality and anterior vitrectomy, were associated with risk of glaucoma-related adverse events.Conclusions and RelevanceIn this cohort study, glaucoma-related adverse events were common after cataract surgery in children; age less than 3 months at surgery was associated with elevated risk of the adverse events in aphakic eyes. Children with pseudophakia, who were older at surgery, less frequently developed a glaucoma-related adverse event within 5 years of lensectomy. The findings suggest that ongoing monitoring for the development of glaucoma is needed after lensectomy at any age.
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers
Sugier, Pierre‐Emmanuel , Lucotte, Elise A. , Domenighetti, Cloé , Law, Matthew H. , Iles, Mark M. , Brown, Kevin M. , McKay, James , Hung, Rayjean J., Karimi, Mojgan, Bacq‐Daian, Delphine, Boland, Anne , Kesminiene, Ausrele , Vathaire, Florent de , Guénel, Pascal , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , May, Patrick , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Nakayama, Akiyoshi , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P.C. van de , Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Ygland, Emil , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Hung, Rayjean J. , Schulte, Claudia , Grover, Sandeep , May, Patrick , Bobbili, Dheeraj R , Zimprich, Alexander , Lang, Anthony E , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Deutschländer, Angela B , Hadjigeorgiou, Georges M., Stefanis, Leonidas , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Ferreira, Joaquim J , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Hung, Rayjean J , Puschmann, Andreas , Guénel, Pascal , Law, Matthew H , Iles, Mark M , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Amos, Christopher I. , Olaso, Robert , Deleuze, Jean‐François , Lesueur, Fabienne , Ostroumova, Evgenia , Schulte, Claudia , Bobbili, Dheeraj Reddy , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Dardiotis, Efthimios , Simitsi, Athina‐Maria , Valente, Enza Maria , Zecchinelli, Anna , Pezzoli, Gianni , Gagliardi, Monica , Matsuo, Hirotaka , Hattori, Nobutaka , Nishioka, Kenya , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Clarke, Carl E , Farrer, Matthew J. , Truong, Thérèse , Elbaz, Alexis

Mayo Clinic

Movement Disorders | February 14, 2023 | Volume: 38 | Issue: 4 | Pages: 604-615

10.1002/mds.29337 | PMID 36788297 Get It

Abstract Background Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties. Objective We used results from genome‐wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors. Methods We used individual data for participants of European ancestry from the Courage‐PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta‐Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa, using cross‐phenotypes polygenic risk score (PRS) analyses. Results We confirmed a previously reported positive genetic correlation of PD with melanoma (G corr = 0.16 [0.04; 0.28]) and reported an additional significant positive correlation of PD with prostate cancer (G corr = 0.11 [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the NSF gene (17q21.31). Conclusions We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Morra, Anna , Andrulis, Irene L. , Beckmann, Matthias W. , Bolla, Manjeet K. , Camp, Nicola J. , Cessna, Melissa H., Chang‐Claude, Jenny , Collaborators, NBCS, Daly, Mary B., Easton, Douglas F. , Eccles, Diana M., Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Gündert, Melanie , Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harrington, Patricia, Hoppe, Reiner , Howell, Anthony , Investigators, ABCTB, Investigators, kConFab, Janni, Wolfgang, Johnson, Nichola , Kristensen, Vessela N. , Lindblom, Annika , Mannermaa, Arto , Mavroudis, Dimitrios, Nevelsteen, Ines, Neven, Patrick , Obi, Nadia , Offit, Kenneth , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Phillips, Kelly‐Anne , Plaseska-Karanfilska, Dijana, Rack, Brigitte , Rhenius, Valerie , Sawyer, Elinor J. , Schmutzler, Rita K. , Schuetze, Sabine, Shah, Mitul , Smichkoska, Snezhana , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Vachon, Celine M. , Veen, Elke M. van , Wang, Qin , Wendt, Camilla, Wildiers, Hans , Adank, Muriel A. , Hooning, Maartje J. , Eccles, Diana , Plaseska‐Karanfilska, Dijana , Eccles, Diana , Evans, D Gareth , García-Closas, Montserrat , Phillips, Kelly-Anne , Wildiers, Hans , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Schreurs, Maartje A. C. , Anton‐Culver, Hoda , Augustinsson, Annelie , Behrens, Sabine , Bojesen, Stig E. , Brauch, Hiltrud , Broeks, Annegien , Buys, Saundra S. , Castelao, Jose E. , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Dennis, Joe , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Eriksson, Mikael , Fehm, Tanja , Figueroa, Jonine D. , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Graßmann, Felix , Hartikainen, Jaana M. , Hopper, John L. , Houlston, Richard S. , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Jones, Michael E. , Kurian, Allison W. , Lambrechts, Diether , Marchand, Loı̈c Le , Lubiński, Jan , Lux, Michael P. , Mulligan, Anna Marie , Muranen, Taru , Nevanlinna, Heli , Newman, William G. , Olshan, Andrew F. , Peterlongo, Paolo , Polley, Eric C. , Presneau, Nadège , Pylkäs, Katri , Radice, Paolo , Rashid, Muhammad Usman , Robson, Mark E. , Romero, Atocha , Saloustros, Emmanouil , Scott, Christopher, Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Tomczyk, Katarzyna , Troester, Melissa A. , Vachon, Celine M. , Winqvist, Robert , Ziogas, Argyrios , Hall, Per N , Pharoah, Paul D.P. , Hollestelle, Antoinette , Schmidt, Marjanka K.

Mayo Clinic

No container title available | February 13, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2569372/v1 | PMID 36824750 Get It

Abstract Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55–0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09–1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words)
Design and quality control of large-scale two-sample Mendelian randomization studies
Haycock, Philip , Borges, Maria Carolina , Burrows, Kimberley , Harrison, Sean , Burgess, Stephen , Chang, Xuling , Khankari, Nikhil K. , Tsilidis, Kostas K, Gaunt, Tom R. , Hemani, Gibran , Zheng, Jie , Truong, Thérèse , Law, Matthew H. , Mariosa, Daniela , Hung, Rayjean J, Smith, George Davey , Relton, Caroline L. , Martin, Richard M. , Peters, Ulrike , Rice, Terri, Gallinger, Steve, Cornish, Alex J. , Vijayakrishnan, Jayaram , Wrensch, Margaret , Korat, Andres V Ardisson , Wheeler, Bill, Nilsson, Björn , Smith, Caren E. , Riadi, David, Claus, Elizabeth B. , Hosnijeh, Ng, Irene Oi‐Lin , Passow, Jeanette E, Han, Jiali , Schildkraut, Joellen M. , Wiemels, Joseph L. , Yang, Keming , Wu, Lang , Boutron, Marie-Christine, Iles, Mark M. , Stanulla, Martin , Gaudet, Mia M., Lenha, Mobuchon, Camp, Nicki J, Sham, Pak C. , Brennan, Paul , Jenkins, Robert B. , Diskin, Sharon J. , Berndt, Sonja I. , Tsavachidis, Spiridon, Channock, Stephen J., Galesloot, Tessel E. , Haycock, Philip , Harrison, Sean , Chang, Xuling , Zheng, Jie , Law, Matthew H , Birmann, Brenda M , Mariosa, Daniela , Zheng, Wei , Davey Smith, George , Borges, Maria C , Martin, Richard M , Iles, Mark M , Truong, Therese , Lemaître, Rozenn N. , Westra, Jason , Tsilidis, Kostas K, O’Mara, Tracy A. , Spurdle, Amanda B. , Slager, Susan L. , Birmann, Brenda M. , Hosnijeh, Fatemeh Saberi , Amos, Christopher I. , Hung, Rayjean J, Zheng, Wei , Gunter, Marc J. , Tintle, Nathan , Cheng, Iona C. , Jenkins, Mark A. , Sud, Amit , Johansson, Mattias , Norman, Aaron D. , Klein, Alison P. , Clay‐Gilmour, Alyssa , Franke, André , Heng, Chew‐Kiat , Song, Ci , Ellinghaus, Eva , Ostroumova, Evgenia , Vathaire, Florent de , Cugliari, Giovanni , Matullo, Giuseppe , Cerhan, James R. , Passow, Jeanette E. Eckel, Foo, Jia Nee , Liu, Jianjun , Barnholtz‐Sloan, Jill S. , Maris, John M. , Hemminki, Kari , Kiemeney, Lambertus A. , Ámundadóttir, Laufey T. , Stern, Marc‐Henri , Purdue, Mark P. , Bondy, Melissa L. , Guénel, Pascal , Taylor, Philip R. , Gharahkhani, Puya , Ostrom, Quinn T. , Stolzenberg‐Solomon, Rachael Z. , Dorajoo, Rajkumar , Houlston, Richard S. , Enroth, Stefan , Harrison, Tabitha A. , Gyllensten, Ulf B , Vijai, Joseph , Shi, Yufang , Yang, Wenjian , Lin, Yi , Van Den Eeden, Stephen K

Mayo Clinic

International Journal of Epidemiology | February 11, 2023 | Volume: 52 | Issue: 5 | Pages: 1498-1521

10.1093/ije/dyad018 | PMID 38587501 Get It

Abstract Background Mendelian randomization (MR) studies are susceptible to metadata errors (e.g. incorrect specification of the effect allele column) and other analytical issues that can introduce substantial bias into analyses. We developed a quality control (QC) pipeline for the Fatty Acids in Cancer Mendelian Randomization Collaboration (FAMRC) that can be used to identify and correct for such errors. Methods We collated summary association statistics from fatty acid and cancer genome-wide association studies (GWAS) and subjected the collated data to a comprehensive QC pipeline. We identified metadata errors through comparison of study-specific statistics to external reference data sets (the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalogue and 1000 genome super populations) and other analytical issues through comparison of reported to expected genetic effect sizes. Comparisons were based on three sets of genetic variants: (i) GWAS hits for fatty acids, (ii) GWAS hits for cancer and (iii) a 1000 genomes reference set. Results We collated summary data from 6 fatty acid and 54 cancer GWAS. Metadata errors and analytical issues with the potential to introduce substantial bias were identified in seven studies (11.6%). After resolving metadata errors and analytical issues, we created a data set of 219 842 genetic associations with 90 cancer types, generated in analyses of 566 665 cancer cases and 1 622 374 controls. Conclusions In this large MR collaboration, 11.6% of included studies were affected by a substantial metadata error or analytical issue. By increasing the integrity of collated summary data prior to their analysis, our protocol can be used to increase the reliability of downstream MR analyses. Our pipeline is available to other researchers via the CheckSumStats package (https://github.com/MRCIEU/CheckSumStats).
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
Le, Hoa , Braun, Kim Van Naarden , Nowakowski, Grzegorz S. , Sermer, David , Radford, John , Townsend, William , Ghesquières, Hervé , Menne, Tobias , Porpaczy, Edit , Schusterbauer, Claudia, Yue, Lihua, Benedetti, Marc De , Hasskarl, Jens, Radford, John , Townsend, William , Fox, Christopher P. , Liu, Fei‐Fei

Mayo Clinic

Leukemia & Lymphoma | February 9, 2023 | Volume: 64 | Issue: 3 | Pages: 573-585

10.1080/10428194.2022.2160200 | PMID 36755418 Get It

The effect of emotion regulation on executive function
Koay, Jun Min , Meter, Anna Van

Mayo Clinic

Journal of Cognitive Psychology | February 9, 2023 | Volume: 35 | Issue: 3 | Pages: 315-329

10.1080/20445911.2023.2172417 | PMID 37791006 Get It

A phase 1 open‐label trial evaluating focused ultrasound unilateral anterior thalamotomy for focal onset epilepsy
Krishna, Vibhor , Mindel, Jesse, Sammartino, Francesco , Gompel, Jamie J. Van , Fountain, Nathan B. , Fisher, Robert S. , Van Gompel, Jamie J , Fountain, Nathan , Fisher, Robert , Block, Cady K. , Dwivedi, Alok

Mayo Clinic

Epilepsia | February 6, 2023 | Volume: 64 | Issue: 4 | Pages: 831-842

10.1111/epi.17535 | PMID 36745000 Get It

AbstractObjectiveFocused ultrasound ablation (FUSA) is an emerging treatment for neurological and psychiatric diseases. We describe the initial experience from a pilot, open‐label, single‐center clinical trial of unilateral anterior nucleus of the thalamus (ANT) FUSA in patients with treatment‐refractory epilepsy.MethodsTwo adult subjects with treatment‐refractory, focal onset epilepsy were recruited. The subjects received ANT FUSA using the Exablate Neuro (Insightec) system. We determined the safety and feasibility (primary outcomes), and changes in seizure frequency (secondary outcome) at 3, 6, and 12 months. Safety was assessed by the absence of side effects, that is, new onset neurological deficits or performance deterioration on neuropsychological testing. Feasibility was defined as the ability to create a lesion within the anterior nucleus. The monthly seizure frequency was compared between baseline and postthalamotomy.ResultsThe patients tolerated the procedure well, without neurological deficits or serious adverse events. One patient experienced a decline in verbal fluency, attention/working memory, and immediate verbal memory. Seizure frequency reduced significantly in both patients; one patient was seizure‐free at 12 months, and in the second patient, the frequency reduced from 90–100 seizures per month to 3–6 seizures per month.SignificanceThis is the first known clinical trial to assess the safety, feasibility, and preliminary efficacy of ANT FUSA in adult patients with treatment‐refractory focal onset epilepsy.